Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0562 in combination with durvalumab or tremelimumab for advanced solid tumors
NL-OMON45907Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of tavolimab, durvalumab and tremelimumab in Nonhematologic neoplasms (2 arms), sponsored by AstraZeneca. Primary endpoint: Safety. Started Oct 2016; status: active, not recruiting.
02
Drugs
tavolimabdurvalumabtremelimumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON45907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45907.